Psychosocial perspectives among cancer patients during the coronavirus disease 2019 (COVID-19) crisis: An observational longitudinal study.
clinical observations
medical oncology
psychosocial studies
quality of life
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
20
05
2021
received:
11
01
2021
accepted:
26
05
2021
pubmed:
19
8
2021
medline:
25
5
2022
entrez:
18
8
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) crisis and consequent changes in medical practice have engendered feelings of distress in diverse populations, potentially adversely affecting the psychological well-being of cancer patients. The purpose of this observational longitudinal study was to evaluate psychosocial perspectives among patients with cancer on intravenous treatment during the COVID-19 pandemic. The study recruited 164 cancer patients undergoing intravenous anti-neoplastic therapy in a tertiary cancer center. Psychosocial indices were assessed at two points in time, corresponding with the beginning of the first wave of COVID-19 pandemic in Israel (March 2020) and the time of easing of restrictions implemented to curtail spread of infection (May 2020). At Time 1 (T1), elevated COVID-19 distress levels (score 1 and 2 on 5-point scale) were observed in 44% of patients, and associated with pre-existing hypertension and lung disease in multivariate analyses but no demographic or cancer related factors. At Time 2 (T2), 10% had elevated anxiety and 24% depression as indicated by Hospital Anxiety and Depression Scale (HADS-A/D). COVID-19 distress at T1 was related to higher levels of HADS-A at T2 (Spearman 0.33 p < .01), but not HADS-D. Patients with breast cancer expressed greater COVID-19 distress compared with other cancer types (p < .01), while both HADS-A and HADS-D were highest for patients with GI cancer. Patient report of loneliness and decreased support from relatives were factors associated with HADS-A (p = .03 and p < .01, respectively), while HADS-D was not similarly related to the factors evaluated. Patients with cancer undergoing intravenous treatment may be vulnerable to acute adverse psychological ramifications of COVID-19, specifically exhibiting high levels of anxiety. These appear unrelated to patient age or disease stage. Those with underlying comorbidities, breast cancer or reduced social support may be at higher risk.
Sections du résumé
BACKGROUND
The coronavirus disease 2019 (COVID-19) crisis and consequent changes in medical practice have engendered feelings of distress in diverse populations, potentially adversely affecting the psychological well-being of cancer patients.
AIM
The purpose of this observational longitudinal study was to evaluate psychosocial perspectives among patients with cancer on intravenous treatment during the COVID-19 pandemic.
METHODS AND RESULTS
The study recruited 164 cancer patients undergoing intravenous anti-neoplastic therapy in a tertiary cancer center. Psychosocial indices were assessed at two points in time, corresponding with the beginning of the first wave of COVID-19 pandemic in Israel (March 2020) and the time of easing of restrictions implemented to curtail spread of infection (May 2020). At Time 1 (T1), elevated COVID-19 distress levels (score 1 and 2 on 5-point scale) were observed in 44% of patients, and associated with pre-existing hypertension and lung disease in multivariate analyses but no demographic or cancer related factors. At Time 2 (T2), 10% had elevated anxiety and 24% depression as indicated by Hospital Anxiety and Depression Scale (HADS-A/D). COVID-19 distress at T1 was related to higher levels of HADS-A at T2 (Spearman 0.33 p < .01), but not HADS-D. Patients with breast cancer expressed greater COVID-19 distress compared with other cancer types (p < .01), while both HADS-A and HADS-D were highest for patients with GI cancer. Patient report of loneliness and decreased support from relatives were factors associated with HADS-A (p = .03 and p < .01, respectively), while HADS-D was not similarly related to the factors evaluated.
CONCLUSION
Patients with cancer undergoing intravenous treatment may be vulnerable to acute adverse psychological ramifications of COVID-19, specifically exhibiting high levels of anxiety. These appear unrelated to patient age or disease stage. Those with underlying comorbidities, breast cancer or reduced social support may be at higher risk.
Identifiants
pubmed: 34405968
doi: 10.1002/cnr2.1506
pmc: PMC8420321
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1506Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
JAMA Netw Open. 2020 May 1;3(5):e2010185
pubmed: 32463467
CNS Spectr. 2020 Feb;25(1):79-100
pubmed: 31010446
Nat Rev Clin Oncol. 2020 Jun;17(6):332-334
pubmed: 32341524
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Front Psychiatry. 2019 Apr 05;10:208
pubmed: 31024362
Cancer Treat Rev. 2017 Jan;52:58-70
pubmed: 27894012
Psychol Med. 2021 Apr;51(6):1052-1053
pubmed: 32216863
World Psychiatry. 2020 Jun;19(2):249-250
pubmed: 32394560
Cancer. 2010 Apr 1;116(7):1810-9
pubmed: 20187099
Breast. 2020 Aug;52:8-16
pubmed: 32334323
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 May 10;41(5):638-641
pubmed: 32164400
Support Care Cancer. 2020 Aug;28(8):3921-3926
pubmed: 31858249
J Clin Oncol. 2020 Jul 1;38(19):2206-2207
pubmed: 32267782
Psychiatry Res. 2020 Sep;291:113190
pubmed: 32563745
Cad Saude Publica. 2020 Apr 30;36(4):e00054020
pubmed: 32374806
Cancer Rep (Hoboken). 2022 May;5(5):e1506
pubmed: 34405968
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Psychooncology. 2014 Feb;23(2):121-30
pubmed: 24105788
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
JAMA Pediatr. 2020 Sep 1;174(9):898-900
pubmed: 32329784
JAMA Netw Open. 2020 Mar 2;3(3):e203976
pubmed: 32202646
Ann Surg Oncol. 2020 Jun;27(6):1717-1720
pubmed: 32270420
BMC Cancer. 2019 Oct 11;19(1):943
pubmed: 31604468
Perspect Psychol Sci. 2015 Mar;10(2):227-37
pubmed: 25910392